Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Line of DNA Amplification Reagents Promises Consistent Results Across All PCR Instruments

By BiotechDaily International staff writers
Posted on 02 Sep 2013
Image: iTaq Universal SYBR Green Supermix (Photo courtesy of Bio-Rad).
Image: iTaq Universal SYBR Green Supermix (Photo courtesy of Bio-Rad).
New reagent mixes specially formulated for PCR applications are now available for biotech and genomics researchers.

Bio-Rad Laboratories, Inc. (Hercules, CA, USA) recently launched two iTaq universal one-step kits aimed to deliver superior data precision and highly efficient reverse transcription quantitative PCR (RT-qPCR) performance under most reaction conditions on any qPCR instrument.

The new iTaq universal one-step kit line includes the iTaq universal SYBR Green one-step kit and the iTaq universal probes one-step kit. Both kits come as a double concentrated, ready-to-use reaction mixes with iScript reverse transcriptase optimized for RT-qPCR.

The iTaq universal SYBR Green one-step kit includes SYBR Green I dye and Bio-Rad’s patented RT inhibitor reducer. The iTaq universal probes one-step kit allows researchers to combine multiple targets in one well (multiplexing), improving data precision and reducing costs.

The new kits enable investigators to obtain reliable and reproducible gene expression-analysis results while amplifying genomic DNA and difficult amplicons with superior efficiency. Results are consistent across real-time instrument platforms under fast or standard conditions.

The Bio-Rad Kits are intended for gene expression analysis, genotyping, mutation detection, and pathogen detection.

Related Links:
Bio-Rad Laboratories, Inc.




Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.